Biomarkers for a successful pregnancy

www.regonline.co.uk/BiomarkPregnanct2013

Thursday, 17 October 2013

Cineworld: The O2, London, SE10 0DX, UK

Successful biomarker profiling in pregnant or prenatal women could not only help predict the pregnancy risk to mothers, but also survival rate of the unborn child and any possible future complications. There is a wide range of possibility for using biomarkers in pregnancy and prenatal testing. For example, research is currently being undertaken to identify biomarkers for

Identifying

· ectopic pregnancy.

· potential rejection of pregnancy by the mother

· possible cardiovascular issues

· maternal autoimmune development

· hypertensive disorders

Assessing

· pregnancy outcome

Revealing

· Maternal Alcohol Consumption

· Maternal tobacco use

Avoiding

· reducing multiple pregnancy

to highlight just a few. This event aims to focus on the current research in this area and discuss the way forward in using biomarkers as a predictive and diagnostic tool to improve pregnancy outcome internationally

This event has CPD accreditation and is part of the 2013 Pregnancy Summit - www.PregnancySummit2013.com

Who Should Attend
Biotech and Pharma Industry Managers: CEOs, Chief Scientists, Group Heads, Senior and Junior Scientists, Research working in the field of biomarkers or pregnancy

Academic and Research Institutes: Group and Lab Heads, Postdoctoral Scientists and Research Students working in the field of biomarkers or pregnancy

Clinicians: Anyone working in the field of pregnancy and diagnosing pregnancy-related illnesses and pregnancy outcome

The Deadline for abstract submissions for oral presentation is July10th 2013
Abstracts for poster presentation only can be submitted up to two weeks before the event
There will be a best poster prize.
You can download the instructions for authors at
www.euroscicon.com/AbstractsForOralAndPosterPresentation.pdf

Talk times include 5 – 10 minutes for questions

Talks include

Ectopic pregnancy biomarkers

Dr Andrew Horne, The Queen’s Medical Research Institute, University of Edinburgh
Ectopic pregnancy is diagnosed using transvaginal ultrasound and serial serum beta-human chorionic gonadotrophin levels. Diagnosis is often delayed and these tests are time-consuming and costly, both psychologically to the patient and financially to health services. The development of a biomarker that differentiates a tubal ectopic from an intrauterine implantation is therefore important. In the pre-genomic era, a one-by-one scientific approach has revealed over 20 candidate biomarkers that could be used as a test to diagnose ectopic pregnancy although at present their clinical utility is very limited. Recent approaches using microarray and proteomic technology have facilitated the identification of further biomarkers.

Screening low risk women for adverse pregnancy outcome
Professor Gordon C S Smith, Professor & Head of Department,Obstetrics and Gynaecology,Cambridge University
Screening low-risk women for the risk of adverse pregnancy outcome, such as pre-eclampsia and fetal growth restricition (FGR), is still largely based on clinical assessment, due to negative trials of new methods. I argue that previous studies have weaknesses in their design and have focused on preterm complications despite the lack of clearly effective interventions to improve outcome. A significant proportion of severe pre-eclampsia and FGR occurs at term and could plausibly be prevented by novel screening tests and early term delivery of high-risk women. It is likely that combining ultrasonic assessment and maternal biomarkers could provide clinically useful prediction of risk.

Additional Confirmed Speakers

Dr KM Gillespie, Diabetes and Metabolism Unit, University of Bristol

Dr Alexander Heazell, Manchester University, UK

Registration Web Site: www.regonline.co.uk/BiomarkPregnanct2013

Bookmark It